亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

医学 安慰剂 双盲 物理疗法 内科学 包涵体肌炎 物理医学与康复 肌炎 病理 替代医学
作者
Michael G. Hanna,Umesh A. Badrising,Olivier Benvéniste,Thomas E. Lloyd,Merrilee Needham,Hector Chinoy,Masashi Aoki,Pedro Machado,Christina Liang,Katrina Reardon,Marianne de Visser,Dana P. Ascherman,Richard J. Barohn,Mazen M. Dimachkie,James Miller,John T. Kissel,Björn Oskarsson,Nanette C. Joyce,Peter Van den Bergh,Jonathan Baets
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:18 (9): 834-844 被引量:139
标识
DOI:10.1016/s1474-4422(19)30200-5
摘要

Inclusion body myositis is an idiopathic inflammatory myopathy and the most common myopathy affecting people older than 50 years. To date, there are no effective drug treatments. We aimed to assess the safety, efficacy, and tolerability of bimagrumab-a fully human monoclonal antibody-in individuals with inclusion body myositis.We did a multicentre, double-blind, placebo-controlled study (RESILIENT) at 38 academic clinical sites in Australia, Europe, Japan, and the USA. Individuals (aged 36-85 years) were eligible for the study if they met modified 2010 Medical Research Council criteria for inclusion body myositis. We randomly assigned participants (1:1:1:1) using a blocked randomisation schedule (block size of four) to either bimagrumab (10 mg/kg, 3 mg/kg, or 1 mg/kg) or placebo matched in appearance to bimagrumab, administered as intravenous infusions every 4 weeks for at least 48 weeks. All study participants, the funder, investigators, site personnel, and people doing assessments were masked to treatment assignment. The primary outcome measure was 6-min walking distance (6MWD), which was assessed at week 52 in the primary analysis population and analysed by intention-to-treat principles. We used a multivariate normal repeated measures model to analyse data for 6MWD. Safety was assessed by recording adverse events and by electrocardiography, echocardiography, haematological testing, urinalysis, and blood chemistry. This trial is registered with ClinicalTrials.gov, number NCT01925209; this report represents the final analysis.Between Sept 26, 2013, and Jan 6, 2016, 251 participants were enrolled to the study, of whom 63 were assigned to each bimagrumab group and 62 were allocated to the placebo group. At week 52, 6MWD change from baseline did not differ between any bimagrumab dose and placebo (least squares mean treatment difference for bimagrumab 10 mg/kg group, 17·6 m, SE 14·3, 99% CI -19·6 to 54·8; p=0·22; for 3 mg/kg group, 18·6 m, 14·2, -18·2 to 55·4; p=0·19; and for 1 mg/kg group, -1·3 m, 14·1, -38·0 to 35·4; p=0·93). 63 (100%) participants in each bimagrumab group and 61 (98%) of 62 in the placebo group had at least one adverse event. Falls were the most frequent adverse event (48 [76%] in the bimagrumab 10 mg/kg group, 55 [87%] in the 3 mg/kg group, 54 [86%] in the 1 mg/kg group, and 52 [84%] in the placebo group). The most frequently reported adverse events with bimagrumab were muscle spasms (32 [51%] in the bimagrumab 10 mg/kg group, 43 [68%] in the 3 mg/kg group, 25 [40%] in the 1 mg/kg group, and 13 [21%] in the placebo group) and diarrhoea (33 [52%], 28 [44%], 20 [32%], and 11 [18%], respectively). Adverse events leading to discontinuation were reported in four (6%) participants in each bimagrumab group compared with one (2%) participant in the placebo group. At least one serious adverse event was reported by 21 (33%) participants in the 10 mg/kg group, 11 (17%) in the 3 mg/kg group, 20 (32%) in the 1 mg/kg group, and 20 (32%) in the placebo group. No significant adverse cardiac effects were recorded on electrocardiography or echocardiography. Two deaths were reported during the study, one attributable to subendocardial myocardial infarction (secondary to gastrointestinal bleeding after an intentional overdose of concomitant sedatives and antidepressants) and one attributable to lung adenocarcinoma. Neither death was considered by the investigator to be related to bimagrumab.Bimagrumab showed a good safety profile, relative to placebo, in individuals with inclusion body myositis but did not improve 6MWD. The strengths of our study are that, to the best of our knowledge, it is the largest randomised controlled trial done in people with inclusion body myositis, and it provides important natural history data over 12 months.Novartis Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
帅气逼人发布了新的文献求助10
2秒前
6秒前
田様的应助被kali采纳,获得10
6秒前
6秒前
Hayat的应助被科研通管家采纳,获得30
6秒前
大只佬的应助被科研通管家采纳,获得10
6秒前
斯文败类的应助被佳佳采纳,获得10
12秒前
15秒前
18秒前
悦耳向松完成签到,获得积分10
19秒前
zhiwei发布了新的文献求助10
19秒前
21秒前
cjhsci发布了新的文献求助10
22秒前
24秒前
萧雨墨发布了新的文献求助10
29秒前
九星完成签到 ,获得积分10
32秒前
慕青的应助被yao采纳,获得10
34秒前
36秒前
38秒前
40秒前
42秒前
44秒前
萧雨墨发布了新的文献求助10
46秒前
LuXiaoyu的应助被Mooncloud采纳,获得10
52秒前
丘比特的应助被的速度采纳,获得10
52秒前
54秒前
57秒前
自觉的河马关注了科研通微信公众号
58秒前
1分钟前
华仔的应助被拉长的远侵采纳,获得10
1分钟前
xinjiu发布了新的文献求助10
1分钟前
1分钟前
刘刘完成签到 ,获得积分10
1分钟前
1分钟前
jianglan完成签到,获得积分10
1分钟前
zhiwei发布了新的文献求助10
1分钟前
汉堡包的应助被胡图图采纳,获得10
1分钟前
昌莆完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577194
关于积分的说明 21851931
捐赠科研通 7788156
什么是DOI,文献DOI怎么找? 3436234
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792